

Review of Results from MS/MS Pre-Conference Survey

APHL Newborn Screening QA/QC
Subcommittee

Presented by Arthur Hagar




“Missed” Cases

- Missed or Delayed Diagnosis ???

# of Cases	Disease
≥ 5	MSUD, TYR 1, Cib C/D, PKU
4	VLCAD, PA/MMA, BKT
3	MCAD, ASA, CUD
2	OTC, CPT II, SCAD, HCU
1	GA I, GA II, LCHAD, 2MBD, HHH

Who Determines “Missed” Cases



Reasons for “Missed” Cases

- Value of Marker Less Than the Cutoff Value
 - Occasionally “close” or borderline
 - Often mild or variant cases
- Marker Not Appropriate
 - Tyrosine instead of SUAC for TYR, Type 1
- Problem With Algorithm ???
- Infant on TPN
- Condition Not on Panel (e.g., Cbl C/D)


Corrective Action

- Nothing
- Change Cutoff Value(s)
 - May result in more false positives
- Change Marker
 - Tyrosine to SUAC for TYR, Type 1
- Add Marker(s) or Ratios
 - Leu/Ala for MSUD
 - C16 + C18:1 for CPT-II

Corrective Action

- Add Tiers
 - Age, weight, gestational age
- Change Protocol
 - Active follow-up of infants on TPN
- Add Second Tier Test
 - Ex: molecular tests
- Use of Region 4 Tools
 - How to implement in screening lab?


Frequency of Cutoff Review



Cutoff Review

- Routinely – 25%
- Occasionally – 54%
- Other Responses – 21%
 - False negative (missed case)
 - Increase in false positives
 - When new standards are used
 - Change in reagent kit lot
 - Request of medical director


Frequency of Routine Review




Routine Review of Cutoffs

- WHY?
 - To decrease the number of false positives without missing cases
 - To ensure that there are no population shifts
 - To ensure comparability between instruments
 - New kit lot
 - Seasonal effects
- WHO?
- HOW?


Occasional Review of Cutoffs – When?



Final Decision to Change Cutoffs




Are Clients Notified



Question 11

- Rather than updating your cutoffs, do you take any other type of corrective action when you encounter a scenario that may require a cutoff change?

Question 11 Responses



Question 11 – Other Responses

- Review interpretation algorithm
- Add secondary marker(s) and ratios
- Review possible effect of age, GA, season
- If due to reagent lot change, may wait out
- Check instruments
 - Review maintenance records
 - Consult vendor engineer
 - Perform instrument comparison

Question 12

- If applicable, what type of corrective action do you take when you encounter a scenario that may require a cutoff change?

Corrective Actions in Situations that May Require a Change in Cutoffs

- Review of six months of data
 - normals, abnormal, missed cases
- Statistical analysis and study
- Correlate change in number of call outs and confirmed cases
- Full investigation
 - Shifts in means of controls or patients
 - Retest old specimens (confirmed cases & borderline results) and PT samples

Acknowledgements

- QA/QC Subcommittee
 - Patrick Hopkins, Chair - MO
 - Neena Champaigne - SC
 - Fizza Gulamali-Majid - MD
 - Art Hagar - GA
 - Patty Hunt - TX
 - Joe Orsini - NY
 - Santosh Shaunak - WA
 - Eleanor Stanley - MI
- CDC
 - Victor de Jesús
 - Joanne Mei
- APHL
 - Jelili Ojodu
 - Guisou Piñeyro
 - OluwaFunke Akinsola
 - Ruhiiyyih Degeberg
- GPHL
 - Betelehem Alemayehu



Breakout Group Topics



Missed Case/Delayed Diagnosis

- Is it a missed case or delayed diagnosis?
 - What is the difference between the two?
 - Are there different implications?
- How are missed cases identified?
 - How do they come to the lab's attention?
 - What is your mechanism for picking them up?
- Are conditions not on your panel counted?
 - What are the implications of either choice?

Barriers to Changing Markers

- Compile a list of barriers
 - Categorize as administrative or technical
- Discuss possible solutions/approaches

Barriers to Method Selection

- Is an FDA-cleared/approved kit required?
- What are the barriers to using a laboratory-developed test (LDT)?
- Is implementation of second-tier tests feasible?
 - What are the advantages and disadvantages?
- Discuss possible solutions/approaches

Cutoff Reviews

- How often are cutoffs reviewed?
 - How often should they be reviewed?
- Who does the review?
 - Who should be involved in the review?
- What data are used when reviewing cutoffs?

- Discuss possible solutions/approaches

Use of Ratios and Enhanced Interpretation Schemes

- Are ratios included in the laboratory report?
- How would you report an enhanced interpretation scheme?
- What are the barriers to using ratios or enhanced interpretation schemes?
 - Ex: use of ratios or an enhanced interpretation scheme with a FDA-approved kit?
- Discuss possible solutions/approaches

Quality Assurance: Corrective and Preventative Action Procedures

- What are the common QA failures in the lab?
- What are the common triggers of CAPA Procedures?
- Review examples of CAPA investigations.
- Discuss possible solutions/approaches